) | |
| Clinical data | |
|---|---|
| Trade names | Fraxiparin(e), Fraxodi, others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Subcutaneous injection (except for haemodialysis) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 89% (SC dose) |
| Elimination half-life | 3.7 hours (SC dose) |
| Excretion | clearance 21.4mL/min (+/- 7) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.029.698  |
| Chemical and physical data | |
| Molar mass | 4300 g/mol |
| (verify) | |
Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.
Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.[1]
For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.[1]
References
- ^ a b "Fraxiparine PRODUCT MONOGRAPH (Canada)" (PDF). Aspripharma.com. Retrieved 2 April 2019.
External links
- "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 2 April 2019.
- Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417. S2CID 95878036.